|
08 Oct 2020 |
TIO Bioventures Launches TCRyption Inc., a Novel TCR-T cell based Immunotherapy Company
|
|
08 Oct 2020 |
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
|
|
08 Oct 2020 |
OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Théa to Develop siRNA Therapeutics for Ophthalmic Diseases
|
|
08 Oct 2020 |
Sensei Biotherapeutics Announces $28.5 Million Financing To Advance Clinical Pipeline and Immunophage™ Platform Targeting Multiple Cancers
|
|
08 Oct 2020 |
Translate Bio Highlights mRNA Platform Potential for the Treatment of Cystic Fibrosis (CF) at the 34th Annual North American Cystic Fibrosis Conference
|
|
07 Oct 2020 |
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs
|
|
07 Oct 2020 |
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment
|
|
06 Oct 2020 |
First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma
|
|
06 Oct 2020 |
AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome
|
|
06 Oct 2020 |
Eureka Therapeutics Announces Initiation of ARYA-1 Clinical Trial to Evaluate ET140203 ARTEMIS® T Cell Therapy in Hepatocellular Carcinoma
|
|
06 Oct 2020 |
Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies
|
|
02 Oct 2020 |
bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)
|
|
02 Oct 2020 |
Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy)
|
|
02 Oct 2020 |
Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial
|
|
02 Oct 2020 |
Mesoblast Receives Complete Response Letter From the FDA for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
|
|
01 Oct 2020 |
Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six
|
|
30 Sep 2020 |
Locus Biosciences signs contract with BARDA to advance $144 million precision medicine program to develop LBP-EC01, a crPhage™ product
|
|
29 Sep 2020 |
Orgenesis announces agreement to acquire Koligo Therapeutics, a leader in personalized cell therapies
|
|
29 Sep 2020 |
Kuur Therapeutics Announces First Patients Dosed with Allogeneic CAR-NKT Cell Therapy
|
|
29 Sep 2020 |
Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis
|
|
29 Sep 2020 |
Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment
|
|
29 Sep 2020 |
Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC
|
|
28 Sep 2020 |
Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
|
|
28 Sep 2020 |
Sarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Functional Improvements 18-months After Administration
|
|
25 Sep 2020 |
OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial
|
